Incretin Atlas › Molecules › Exenatide
Exenatide
GLP-1 · s.c. · AstraZeneca
Summary
- Also known as
- Bydureon / Byetta
- Mechanism
- GLP-1
- Route
- s.c.
- Company
- AstraZeneca
- Highest development stage
- —
- Status (as of data cut)
- Approved (T2D) verify
- Next milestone
- —
Trial arms: weight, HbA1c and tolerability
No trial arms with extracted efficacy or tolerability data yet.
Outcome trials
Cardiovascular and kidney outcome trials
EXSCEL exenatide QW 2 mg vs placebo · T2D, broad CV risk · n = 14752 · 2017 verified
| Endpoint | HR | 95 % CI | Events, drug vs control | Status |
|---|---|---|---|---|
| 3-point MACE primary First occurrence of CV death, nonfatal MI, or nonfatal stroke | 0.91 | 0.83–1.00 | 839 vs 905 | verified |
| Cardiovascular death Death from cardiovascular causes (includes death from unknown cause) | 0.88 | 0.76–1.02 | 340 vs 383 | verified |
| All-cause death Death from any cause | 0.86 | 0.77–0.97 | 507 vs 584 | verified |
| Myocardial infarction Fatal or nonfatal myocardial infarction | 0.97 | 0.85–1.10 | 483 vs 493 | verified |
| Stroke Fatal or nonfatal stroke | 0.85 | 0.70–1.03 | 187 vs 218 | verified |
| Hospitalisation for heart failure Hospitalization for heart failure | 0.94 | 0.78–1.13 | 219 vs 231 | verified |
| Coronary revascularisation Cardiovascular or peripheral revascularization procedures (NOTE: includes peripheral, not coronary-only) | 0.94 | 0.85–1.05 | — | verified |
Verbatim quotes (7)
- 3-point MACE · Results, Primary and Secondary Cardiovascular Outcomes; Tabl
839 of 7356 patients (11.4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396 patients (12.2%; 4.0 events per 100 person-years) (hazard ratio, 0.91; 95% CI, 0.83 to 1.00)
- Cardiovascular death · Table 1
Death from cardiovascular causes 340 (4.6) 1.4 383 (5.2) 1.5 0.88 (0.76–1.02)
- All-cause death · Table 1
Death from any cause 507 (6.9) 2.0 584 (7.9) 2.3 0.86 (0.77–0.97)
- Myocardial infarction · Table 1
Fatal or nonfatal myocardial infarction 483 (6.6) 2.1 493 (6.7) 2.1 0.97 (0.85–1.10)
- Stroke · Table 1
Fatal or nonfatal stroke 187 (2.5) 0.8 218 (2.9) 0.9 0.85 (0.70–1.03)
- Hospitalisation for heart failure · Table 1
Hospitalization for heart failure 219 (3.0) 0.9 231 (3.1) 1.0 0.94 (0.78–1.13)
- Coronary revascularisation · Results, Additional Efficacy Outcomes paragraph
The rate of cardiovascular or peripheral revascularization procedures was similar in the two groups (hazard ratio, 0.94; 95% CI, 0.85 to 1.05)
Registered trials (1)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| EXSCEL Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus | CV outcomes | Phase 3 | completed | 2010-06 → 2017-04 | 14752 | MACE HR 0.91 (0.83–1.00): non-inferior, superiority not shown | NCT01144338 |
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: Exenatide. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/exenatide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.